PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

LOXICOM 0.5 mg/mL ORAL SUSPENSION FOR CATS

Composition:
Each mL contains 0.5mg meloxicam

Action
Meloxicam is a non-steroidal anti-inflammatory compound of the oxicam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leucocyte infiltration into the inflamed tissue and prevents bone and cartilage damage. To a minor extent it also inhibits collagen induced thrombocyte aggregation.

Indications
Loxicom 0.5 mg/mL Oral Suspension For Cats is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as disco-spondylosis, arthropathy and soft tissue injuries.

DIRECTIONS FOR USE
Contraindications
This product is contraindicated for use in pregnant or lactating animals as no data has been established.
As for all NSAIDs use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.
The use of the product is contra-indicated in animals suffering from cardiac, hepatic or clinical renal disease. Older cats considered for chronic treatment should be screened for pre-existing renal, hepatic or gastrointestinal disorders or hypovolaemia (using haematology, serum biochemical analysis and urinalysis as necessary) before administration of Loxicom 0.5 mg/mL Oral Suspension For Cats.
This is also the case when there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product.

Precautions
Loxicom 0.5 mg/mL Oral Suspension should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics or anti-coagulant agents. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment free period with such drugs should be observed for at least 24 hours before commencement with Loxicom 0.5 mg/mL Oral Suspension. The treatment–free period, however, should take into account the pharmacokinetic properties of the drugs used previously.
Avoid use in any dehydrated, hypolvolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Response to long-term therapy should be monitored at three monthly intervals or more frequently as advised by the veterinarian. Regular monitoring of older cats undergoing long-term therapy is particularly important.
Loxicom 0.5 mg/mL Oral Suspension For Cats should not be used following parenteral injection of Loxicom or any other NSAID as appropriate dosage regimes for such follow-up treatments have not been established.

Side Effects
Typical adverse reactions of NSAIDs may occur. These may include loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure. Gastro-intestinal side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious. If gastro-intestinal side effects are persistent or of severity, treatment should be discontinued.

Overdose
In the event of an overdose, adverse reactions are expected to be more severe and more frequent. In case of overdoing a symptomatic treatment should be initiated.

Dosage and Administration
Shake well before use.
Should be administered orally either mixed with food or directly into the mouth around meal times. Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
Particular care should be given with regard to the accuracy and timing of dosing. The recommended dose should not be exceeded. Ensure dose is delivered at the same time each day. Please carefully follow the instructions of the veterinarian.
Dosing procedure using the measuring syringe: The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the maintenance dose. Thus for initiation of the therapy on the first day, twice the maintenance volume will be required. A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.

Dispose of empty container by wrapping with paper and putting in garbage.

Store below 25°C (Air conditioning). Discard 6 months after initial use.

Net contents:
5mL or 15mL or 30mL

Manufactured by:
Norbrook Laboratories
Limited UK

Distributed by:
Norbrook Laboratories Australia Pty Limited
ACN 080 972 596
Unit 7/15- 21 Butler Way,
Tullamarine, VIC 3043

APVMA No.: 64038/101192

342411I01

Norbrook®